Mitochondrial Peptides
An educational resource on the peptides studied for mitochondrial function, cellular energetics, and metabolic health — MOTS-c, SS-31, Humanin, and the broader mitochondrial peptide research space.
On This Page
About This Category
Mitochondrial peptides are a small but rapidly expanding class of compounds studied for their direct effects on mitochondrial function, cellular energetics, and downstream metabolic health. The category includes mitochondrial-derived peptides (MDPs) — short peptides encoded within the mitochondrial genome itself, including MOTS-c, Humanin, and the SHLP family — as well as synthetic peptides like SS-31 (elamipretide) designed to target the inner mitochondrial membrane.
Unlike most therapeutic peptides that act on cell-surface receptors, mitochondrial peptides reach the mitochondria themselves — modulating cardiolipin organization (SS-31), AMPK signaling and metabolic homeostasis (MOTS-c), or apoptotic and stress-response pathways (Humanin). The research interest is driven by their potential application in age-related metabolic decline, mitochondrial disease, cardiac and neurodegenerative conditions, and the broader 'mitochondrial dysfunction as a hallmark of aging' framework.
None of the compounds in this category are FDA-approved for general use. SS-31 (elamipretide) is the most clinically advanced, with phase 3 data in Barth syndrome and ongoing trials in primary mitochondrial myopathy. The remaining compounds — MOTS-c, Humanin, the SHLPs — are investigational and confined to research use.
History & Discovery
The mitochondrial peptide field is recent. Humanin was the first mitochondrial-derived peptide identified — discovered in 2001 by the Nishimoto lab while screening cDNA libraries from the brains of Alzheimer's patients for factors that protected against amyloid-beta toxicity. It overturned the textbook assumption that the mitochondrial genome encoded only the 13 well-known protein subunits of the electron-transport chain.
MOTS-c was identified in 2015 by Pinchas Cohen's lab, demonstrating that the mitochondrial 12S rRNA gene contained an additional functional ORF encoding a peptide with profound effects on systemic metabolism. The Cell Metabolism paper established the AMPK mechanism and the framework for studying mitochondrial peptides as endocrine signaling molecules.
SS-31 has a longer development history. Originally characterized in the early 2000s by Hazel Szeto and Peter Schiller, the cardiolipin-targeting tetrapeptide was developed under the names Bendavia, MTP-131, and ultimately elamipretide. Stealth BioTherapeutics has carried it through multiple clinical programs — initially in cardiac ischemia-reperfusion (where the trials were not successful enough to support that indication), and subsequently into mitochondrial disease, where the more recent Barth syndrome data has been more positive.
The SHLP family was identified later, extending the mitochondrial-peptide concept beyond the original Humanin and MOTS-c discoveries. The field continues to expand as systematic exploration of mitochondrial open reading frames identifies additional functional peptides.
Mechanism of Action
SS-31 (elamipretide / Bendavia) is a small, cell-permeable tetrapeptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) that selectively binds cardiolipin in the inner mitochondrial membrane. By stabilizing cardiolipin, SS-31 protects mitochondrial cristae structure, supports electron-transport-chain efficiency, and reduces the production of reactive oxygen species during oxidative phosphorylation. The mechanism is unusual — most mitochondrial-targeted compounds are antioxidants or substrate analogs; SS-31 is structural.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. It acts on AMPK — the master metabolic sensor — increasing glucose uptake, fatty acid oxidation, and metabolic flexibility. Animal models demonstrate prevention of diet-induced obesity, restoration of insulin sensitivity in aged mice, and improved exercise capacity. MOTS-c levels decline with age in humans, which is part of the rationale for studying it in age-related metabolic decline.
Humanin is a 24-amino-acid peptide encoded within the mitochondrial 16S rRNA gene. It acts as a neuroprotective and cytoprotective factor — protecting cells from amyloid-beta toxicity in Alzheimer's models, modulating apoptosis through binding Bax and IGFBP-3, and acting on a heterotrimeric receptor complex involving CNTFR. Humanin levels also decline with age and correlate with metabolic and cognitive markers.
The SHLP (Small Humanin-Like Peptides) family — SHLP1 through SHLP6 — are additional mitochondrial-derived peptides identified through systematic exploration of the mitochondrial open reading frames. SHLP2 in particular has shown insulin-sensitizing and cytoprotective effects in research models.
Pharmacokinetics
| SS-31 half-life | ~2.5 hours subcutaneous (clinical trial data) |
| MOTS-c half-life (research) | Estimated ~30 minutes; biological effects extend longer via downstream signaling |
| Humanin half-life | Short (minutes); analogs (HNG, AGA-HNG) are longer-acting |
| Routes (research) | Subcutaneous · Intravenous (clinical SS-31) |
| Onset of effect (metabolic markers) | Days to weeks for downstream metabolic endpoints |
| Dosing frequency (research) | Daily or every other day for MOTS-c; daily SS-31 in clinical trials |
Research Use Cases
Age-Related Metabolic Decline (MOTS-c)
MOTS-c is the lead mitochondrial peptide for metabolic research. Animal models demonstrate prevention of diet-induced obesity, restoration of insulin sensitivity in aged mice, improved glucose tolerance, and enhanced exercise capacity in older animals. Endogenous MOTS-c levels decline with age, framing the supplementation hypothesis.
Mitochondrial Disease (SS-31 / Elamipretide)
SS-31 is in clinical trials for Barth syndrome (a rare X-linked cardiolipin disorder) and primary mitochondrial myopathy. The most clinically advanced mitochondrial peptide, with FDA orphan-drug designation in some indications.
Cardiac & Cardiovascular Research (SS-31)
Earlier SS-31 trials targeted ischemia-reperfusion injury and heart failure with preserved ejection fraction. The cardiac trials produced mixed results clinically but solidified the mechanistic understanding of SS-31's effects on mitochondrial function in heart tissue.
Neurodegenerative Research (Humanin)
Humanin is studied in Alzheimer's, Parkinson's, and broader neurodegenerative research for its neuroprotective and anti-apoptotic mechanisms. Long-acting analogs (HNG, AGA-HNG) have been developed for research use.
Exercise Physiology & Performance Research
MOTS-c is studied for its effects on exercise capacity, mitochondrial biogenesis, and muscle metabolism. The cross-talk between exercise, AMPK signaling, and MOTS-c expression is an active research area.
Cellular Stress & Apoptosis Research
Mitochondrial peptides — particularly Humanin and SHLP2 — modulate apoptotic and stress-response pathways. Research applications span ischemic injury, oxidative stress, and chemotherapy-related mitochondrial dysfunction (in supportive-care research, not as cancer treatments).
Research Dosing Reference
MOTS-c — research dosing
Most common research configuration. Cycles typically run 4–12 weeks. Some protocols front-load with 5 mg daily for 1–2 weeks before transitioning to maintenance.
SS-31 / Elamipretide — clinical-trial dosing
Clinical-trial dosing for mitochondrial disease indications. Research use outside trials follows similar daily subQ patterns.
Humanin — research dosing (analog-dependent)
Native Humanin has poor pharmacokinetics; long-acting analogs (HNG, AGA-HNG) are the practical research configuration. Limited human-use data.
MOTS-c + Tesamorelin (metabolic research stack)
Combines MOTS-c's AMPK-mediated insulin-sensitization with tesamorelin's GH-axis effect on visceral adiposity. Common research configuration for metabolic syndrome and visceral-fat research.
Stacking & Combinations
MOTS-c + 5-Amino-1MQ
Combines MOTS-c's AMPK activation with 5-Amino-1MQ's NNMT inhibition (preserves cellular SAM/methylation pools and NAD+ precursor flux). Mechanically complementary at the mitochondrial-energetics layer — both push toward improved metabolic flexibility and fatty-acid oxidation.
MOTS-c + NAD+ / NMN
Pairs the AMPK-mediated metabolic effects of MOTS-c with NAD+ precursor strategies. NAD+ availability is a known limiting factor for mitochondrial sirtuin activity (SIRT1, SIRT3); MOTS-c provides the upstream signaling. A common 'mitochondrial stack' in longevity research circles.
MOTS-c + Tesamorelin
Combines AMPK-mediated insulin sensitization (MOTS-c) with GH-axis lipolysis specifically affecting visceral fat (tesamorelin). Each mechanism addresses a different lever in the metabolic-syndrome research framework.
SS-31 + Conventional Mitochondrial Disease Care
In clinical-trial settings, SS-31 is studied alongside standard supportive care for mitochondrial disease — coenzyme Q10, riboflavin, creatine, exercise programs. Not a research-stack arrangement; an indication-specific clinical configuration.
Humanin / HNG + Neuroprotective Research
In animal-model research, Humanin and its long-acting analogs are studied alongside other neuroprotective compounds (cerebrolysin, dihexa, cognitive-research peptides) for synergistic effects on neurodegenerative endpoints.
Side Effect Profile
Common / Mild-to-Moderate
- •Injection-site reactions (mild redness, brief discomfort) — most common AE across the category
- •Mild GI symptoms with MOTS-c in some research subjects (uncommon)
- •Mild fatigue at the start of MOTS-c protocols (typically resolves)
- •SS-31 in clinical trials: well-tolerated overall; injection-site reactions and headache reported
- •Transient changes in glucose readings with MOTS-c (insulin sensitization is the intended mechanism)
Serious / Less Common
- •Long-term human safety data is limited or absent for MOTS-c and Humanin outside controlled research settings
- •SS-31 has the most clinical safety data — generally favorable, but mitochondrial disease populations differ from healthy populations
- •Theoretical concern: aggressive AMPK activation (MOTS-c) in subjects with already-low metabolic substrate availability
- •Quality and contamination concerns from unverified suppliers — the dominant real-world risk for research-grade material
The mitochondrial peptide category has a favorable acute safety profile in research and clinical settings to date. Long-term safety beyond the trial windows remains poorly characterized for the research-only compounds (MOTS-c, Humanin). SS-31 has substantial clinical exposure in the mitochondrial disease populations. Sourcing from verified suppliers with batch-specific Certificates of Analysis is the most important practical safety lever.
Storage & Reconstitution
- Lyophilized vials (MOTS-c, SS-31, Humanin) are stored refrigerated at 2–8°C. Stable at room temperature for short shipping intervals; long-term lyophilized storage at -20°C for extended shelf life.
- Reconstitute with bacteriostatic water for injection. Standard concentrations: MOTS-c 10 mg in 2 mL = 5 mg/mL; SS-31 typically prepared at 10–20 mg/mL for research dosing convenience.
- Inject the BAC water against the vial wall slowly. Swirl gently — never shake. Mitochondrial peptides like SS-31 are particularly amphipathic and will foam aggressively if shaken.
- Reconstituted MOTS-c is stable refrigerated for approximately 30+ days for research purposes. SS-31 reconstituted vials should be used within 14–30 days under refrigeration based on clinical-trial handling conventions.
- Use 31G insulin syringes for subcutaneous injection. Rotate sites to avoid lipohypertrophy.
- Mitochondrial peptides are sensitive to light and temperature cycling — minimize freeze-thaw cycles and avoid prolonged room-temperature exposure post-reconstitution.
Key Studies & Trial Data
MOTS-c regulates metabolic homeostasis and exercise capacity
Foundational MOTS-c paper from the Cohen lab. Demonstrated that this 16-amino-acid mitochondrial-derived peptide acts on AMPK, improves insulin sensitivity in mouse models, prevents diet-induced obesity, and enhances exercise capacity — establishing the mechanism that drives current research interest.
Lee C, et al. Cell Metab. 2015;21(3):443–454.
MOTS-c restores insulin sensitivity in aged mice
Follow-up study demonstrating that MOTS-c administration restores insulin sensitivity and improves metabolic flexibility in aged mice — supporting the framework of MOTS-c as a therapeutic candidate in age-related metabolic decline.
Reynolds JC, et al. Aging Cell. 2018; subsequent Cohen lab follow-ups.
Humanin protects against amyloid-beta toxicity (foundational)
Original Humanin discovery paper. Identified through screening cDNA libraries from Alzheimer's patient brains for factors that protected hippocampal neurons from amyloid-beta toxicity. The discovery overturned the assumption that the mitochondrial genome encoded only the 13 known electron-transport-chain subunits.
Hashimoto Y, et al. Proc Natl Acad Sci USA. 2001;98(11):6336–6341.
SS-31 (elamipretide) targets cardiolipin and protects mitochondrial structure
Foundational SS-31 mechanism paper from the Szeto lab. Demonstrated that the cell-permeable tetrapeptide selectively binds cardiolipin in the inner mitochondrial membrane, stabilizes cristae structure, and preserves electron-transport-chain efficiency — the mechanism behind subsequent clinical development.
Zhao K, et al. J Biol Chem. 2004;279(33):34682–34690.
Elamipretide in Barth syndrome (TAZPOWER trial)
Phase 2/3 crossover trial of elamipretide in Barth syndrome — a rare X-linked cardiolipin disorder. The trial did not meet its co-primary endpoints (6-minute walk test and patient-reported assessment), but open-label extension data showed improvements in muscle strength and several functional measures over time. The mixed result reflects the difficulty of running powered trials in ultra-rare disease populations and has informed Stealth's subsequent development strategy.
Reid Thompson W, et al. Genet Med. 2021;23(3):471–478.
Comparisons & Deep Dives
In-depth articles on Peptide Basics that compare Mitochondrial Peptides to related compounds and expand on its mechanism and use.
How GLP-1 Works for Weight Loss
Mitochondrial peptides act on the metabolic-flexibility side of body composition; GLP-1 agonists act on appetite. This explainer covers the GLP-1 mechanism for context on how mitochondrial peptides differ.
Insulin Sensitivity & Appetite Peptides
An overview of the peptides that act on insulin signaling and appetite regulation — useful background for understanding where MOTS-c sits in the broader metabolic-peptide landscape.
What Are Peptides?
Foundational explainer on peptides as a drug class — useful background on why mitochondrial peptides are mechanically distinct from cell-surface-receptor agonists.
Are Peptides Safe?
A practical overview of peptide safety — the difference between FDA-approved peptide drugs (like elamipretide in clinical trials) and research-only compounds.
Best Peptides for Fat Loss
Many mitochondrial peptides (MOTS-c in particular) appear in body-recomposition discussions. This piece covers the broader fat-loss peptide landscape.
Frequently Asked Questions
Where to Source Research-Grade Mitochondrial Peptides
Base Peptide
Research-grade MOTS-c, SS-31, Humanin, and the wider mitochondrial peptide lineup with batch-specific Certificates of Analysis. The standard sourcing reference for the mitochondrial-peptide research community.
Other reputable suppliers known for batch-specific Certificates of Analysis:
Want a deeper, ongoing reference? Peptide Basics maintains a comprehensive resource on mitochondrial peptides alongside calculators, reconstitution guides, and a database of 60+ research peptides.
Read more on Peptide Basics